About CAMP4 Therapeutics
CAMP4 Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat genetic diseases. Its RAP Platform systematically maps regulatory RNAs (regRNAs) across human tissues and designs antisense oligonucleotide (ASO) candidates targeting those regRNAs. Lead programs include CMP-CPS-001 for urea cycle disorders and CMP-002 for SYNGAP1-related disorder.
Company details
Funding
Total raised
$100M
Last stage
Growth
Investors
Founders
Josh Mandel-Brehm
Co-founder and CEO of CAMP4 Therapeutics, leading the company since its early stages through Series A, Series B, and IPO on Nasdaq (October 2024).
LinkedInRick Young
Professor of Biology and core member of the Whitehead Institute at MIT; discoverer of regulatory RNAs (regRNAs), which form the scientific basis of CAMP4's RAP Platform.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.